

ASX Announcement

The Manager
Company Announcements Office
Australian Securities Exchange
20 Bridge Street
SYDNEY NSW 2000

Dear Sir or Madam

NOTIFICATION UNDER TO SECTION 708A(5)(e) OF THE CORPORATIONS ACT 2001

This notice is given by PYC Therapeutics Limited (ACN 098 391 961), (**ASX:PYC**) (**'PYC'** or **'the Company'**) under section 708A(5)(e) of the Corporations Act 2001 (Cth) (**'the Act'**).

PYC today released an Appendix 2A for the issue of 316,363,641 shares relating to Tranche 2 of the Placement announced on 11 May 2023. These securities above were issued without disclosure under Part 6D.2 of the Corporation Act.

PYC gives notice under section 708A(5)(e) of the Act that:

- (a) The shares were issued without disclosure to investors under Part 6D.2 of the Act;
- (b) As a disclosing entity, PYC is subject to regular reporting and disclosure obligations;
- (c) As at the date of this notice, PYC has complied with the provisions of Chapter 2M as they apply to PYC and section 674 of the Act; and
- (d) As at the date of his notice, there is no information that is 'excluded information' within the meaning of section 708A(7) and 708A(8) of the Act which is required to be disclosed by Po Valley under section 708A(6)(e) of the Act.

Approved and authorised for release by the Board of Directors of PYC Therapeutics Limited

Kevin Hart
Company Secretary

About PYC Therapeutics

PYC Therapeutics (ASX: PYC) is a clinical-stage biotechnology company creating a new generation of RNA therapies to change the lives of patients with genetic diseases. The Company utilises its proprietary drug delivery platform to enhance the potency of precision medicines within the rapidly growing and commercially proven RNA therapeutic class. PYC's drug development programs target monogenic diseases – **the indications with the highest likelihood of success in clinical development**¹.

The Company was the first to progress a drug candidate for a blinding eye disease of childhood into human trials and is now progressing multiple 'fast-follower' programs into the clinic. For more information, visit pyctx.com, or follow us on [LinkedIn](#) and [Twitter](#).

CONTACTS:

INVESTORS and MEDIA

info@pyctx.com

1. Advancing Human Genetics Research and Drug Discovery through Exome Sequencing of the UK Biobank
<https://doi.org/10.1101/2020.11.02.2022232>